Other Current Assets

6 Months Ended

Jun. 30, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets

4. Other Current Assets

As of June 30, 2017, Other Current Assets included prepaid expenses of $1.0 million, comprised primarily of prepayments made to the Company’s clinical research organization for our clinical trials for prexigebersen in AML and CML of $0.7 million and other prepaid expenses of $0.3 million. As of December 31, 2016, Other Current Assets included prepaid expenses of $0.9 million.